Prime Medicine is eliminating 25% of its workforce in a restructuring that includes the company pivoting its prime editing-based pipeline focus to liver disease and programs funded by external ...

The Cambridge biotech's wild ambitions for a powerful gene editing technology sank as the biotech market slumped.

Prime Medicine’s Pipeline: Prime Medicine is advancing a set of high-value programs across its core areas of focus ...

Q1 2025 Management View Jacqui Shea, President and CEO, highlighted that Inovio remains on track to submit its BLA for ...

Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal ...

Disc Medicine, Inc. announced significant advancements ... efforts for bitopertin as well as development of the rest of our pipeline. We expect data from ongoing trials of DISC-0974, the Phase ...

“This quarter we continued to advance our promising neurology genomic medicine pipeline and are pleased to have signed our third STAC-BBB license agreement, reinforcing that Sangamo is a ...

In this blog, Bioinformatics Engineer Ege Ulgen shares his experience working in the Cancer Short Reads Team at Genomics ...

Strategic priorities did not shift markedly, with primary attention on INO-3107's advancement and the next-generation DNA medicine platform. Management acknowledged the evolving nature of tariffs ...